Gene signature discovery and systematic validation across diverse clinical cohorts for TB prognosis and response to treatment
Fig 6
Model validation using the Leicester TB treatment study.
(A) The distributions of the reduced model–generated TB scores, stratified by different time intervals after treatment initiation and healthy control, are shown in the violin plot. Individual datapoints are plotted as a point in the violin plot (datapoints n = 728). (B) Receiver operating characteristic curves depict model discrimination between healthy controls and the patients from different time intervals after treatment initiation. Area under the curve and 95% confidence intervals for each interval to disease are also shown. Comparison of TB scores between smear positive and negative patients at TB diagnosis (C), between the patients requiring standard and extended anti–TB treatment (ATT) at week 3–4 (D), month 2–3 (E) and month 4–6 (F) after treatment initiation are shown in the violin plots. P–values were calculated using the Mann–Whitney U test (ns, p < 1; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001). (G) Scatterplots show TB scores throughout treatment course, color–coded by the patients requiring standard or extended ATT. The line represents the median of the stratified group with 95% confidence interval around the median shown in the shaded area. (F) ROC curves, stratified by different timepoints after treatment initiation, depict predictive performance of the models for discrimination between the patients requiring standard and extended ATT.